| [1] |
QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao.
Research Progress in Integration Sites for Cellular and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
|
| [2] |
ZHU Huijuan, REN Jingtian.
Safety Risks of Human Rabies Immunoglobulin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
|
| [3] |
LI Can, LIU Lehuan, CHEN Xia, QU Jianbo.
Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
|
| [4] |
LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui.
Developments and Prospects of Radiopharmaceuticals in China
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
|
| [5] |
YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng.
Quality standard for licorice of different sources
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028.
|
| [6] |
WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng.
Evaluation of drug safety with multicenter real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
|
| [7] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
| [8] |
LI Wenpeng, ZHOU Huziwei, ZHU Lan, WANG Shengfeng.
Applications and progress of methods for estimating opioids requirements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 519-523.
|
| [9] |
QIU Jinghui, ZHOU Huziwei, CAO Ying, LI Wenpeng, WANG Shengfeng.
Research progress on the influencing factors and intervention measures of opioid requirements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 524-528.
|
| [10] |
CAO Ying, ZHOU Huziwei, ZHU Lan, WANG Shengfeng.
Management of compound glycyrrhiza oral solution and recommendations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 529-534.
|
| [11] |
ZHOU Yue, LIU Shuo, SONG Haibo.
Roles of licensed pharmacists in drug classification management
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 428-434.
|
| [12] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|
| [13] |
JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling.
Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
|
| [14] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
| [15] |
MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe.
Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32.
|
